Measles, mumps, and rubella virus vaccine (M-M-R™II): A review of 32 years of clinical and postmarketing experience

► The 32-year safety profile of M-M-R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1 × 106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated.